Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in the Treatment of Adult Patients With Community-Acquired Bacterial Pneumonia

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in the Treatment of Adult Patients With Community-Acquired Bacterial Pneumonia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Solithromycin (Primary) ; Moxifloxacin
  • Indications Community-acquired pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms SOLITAIRE-ORAL
  • Sponsors Cempra Pharmaceuticals; Melinta Therapeutics

    • Most Recent Events

    • 25 Apr 2017 Results of subgroup analysis of two phase III studies (NCT01756339 and NCT01968733) assessing response by geographical region, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases.
    • 25 Apr 2017 Results of pooled analysis (n=785) assessing early clinical response from two phase III studies (NCT01756339 and NCT01968733) in microbiologically positive subjects, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases.
    • 25 Apr 2017 Results of comparative efficacy across patient age subpopulations data from two phase III study (SOLITAIRE-Oral and SOLITAIRE-IV) presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top